Zandelisib is an investigational new drug that is being evaluated to treat follicular lymphoma. It is a phosphatidylinositol 3 kinase delta inhibitor....
2 KB (69 words) - 08:49, 12 September 2024
benefit in the phase III trial SANDPIPER in patients with breast cancer. Zandelisib (codenamed ME-401; PIK3CD inhibitor) will be tested as a potential treatment...
45 KB (5,359 words) - 22:07, 19 July 2024